Doubrovinskaia, S., Korporal-Kuhnke, M., Jarius, S., Haas, J., & Wildemann, B. (2023). Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): Fatal outcome. Journal of neurology, 271(5), . https://doi.org/10.1007/s00415-023-12071-9
Chicago-Zitierstil (17. Ausg.)Doubrovinskaia, Sofia, Mirjam Korporal-Kuhnke, Sven Jarius, Jürgen Haas, und Brigitte Wildemann. "Newly Emerging Type B Insulin Resistance (TBIR) During Treatment with Eculizumab for AQP4-IgG-positive Neuromyelitis Optica Spectrum Disorder (NMOSD): Fatal Outcome." Journal of Neurology 271, no. 5 (2023). https://doi.org/10.1007/s00415-023-12071-9.
MLA-Zitierstil (9. Ausg.)Doubrovinskaia, Sofia, et al. "Newly Emerging Type B Insulin Resistance (TBIR) During Treatment with Eculizumab for AQP4-IgG-positive Neuromyelitis Optica Spectrum Disorder (NMOSD): Fatal Outcome." Journal of Neurology, vol. 271, no. 5, 2023, https://doi.org/10.1007/s00415-023-12071-9.